52-week adjusted-price high
ActiveAdjusted close first reaches a 252-trading-day high; repeated hits within 20 days count once.
Free trial
Ask AI to review this stock
Copy the prompt to get recent events, historical reactions, and a short research brief.
Tell your AI:
Help me set up FinLab and analyze ABCL AbCellera Biologics Inc.. Please read: https://finlab.finance/en/setup?stock=ABCL
ABCL
AbCellera Biologics Inc. Healthcare As of 2026-08-24 Updated daily after market close
quality needs a look, discounted valuation.
Is AbCellera Biologics Inc. a buy? Fundamentals and valuation first
-
Quality is weaker than peers. Operating margin is only around the 9th percentile. TTM ROE is about -15.3%.
-
Valuation is cheaper than most peers. TTM P/E is in the 11th percentile, lower than most liquid US common stocks.
-
Recent volatility is elevated. 60-day annualized volatility is in the 90th percentile. Average 20-day dollar volume is about $94.5M.
-
Signals are active now. 52-week adjusted-price high, Top-quintile 6-month momentum, Filed revenue acceleration currently holds; the tables below show what followed in this stock’s own history.
Watchlist
This page refreshes daily after the close. Add AbCellera Biologics Inc. to your watchlist to track signal changes on your next visit.
Historical evidence
Signals active now
Each active condition is tested against this stock’s own history and benchmarked versus the S&P 500.
Top-quintile 6-month momentum
Active · now 99.8303647158609%The stock ranks in the top 20% of the liquid US common-stock universe by 126-day adjusted return.
Average forward return after Top-quintile 6-month momentum。20-day: Win 80%, Sample 5, Median +11.17%, Excess +5.54%, Beat mkt rate 80%；60-day: Win 60%, Sample 5, Median +12.91%, Excess +24.38%, Beat mkt rate 80%
60 days after: historical avg +25.47%
20-day +7.43%
60-day +25.47%
20-day
60-day
Win
80%
60%
Sample
5
5
Median
+11.17%
+12.91%
Excess
+5.54%
+24.38%
Beat mkt rate
80%
80%
Over 5 occurrences, 60-day forward avg gained 25.47%, beat the market by 24.38 pts; win rate 60%.
Filed revenue acceleration
Active · now 242.66493618862214%TTM revenue growth is at least 10% and improved versus the prior filed quarter; event date is the SEC filing date.
Market-wide momentum baseline
Across 97,693 liquid US common-stock samples, top-quintile 6-month momentum was followed by an average 60-trading-day return of +6.20%, a 58.1% positive-return rate, and +2.84 percentage points of average excess return versus the S&P 500.
Baseline: weekly samples since 2016 where a liquid US common stock ranked in the top quintile by 126-trading-day momentum. Forward return is 60 trading days; excess return is versus S&P 500 (^GSPC).
Signals not active now
Inactive signals still show the stock-specific historical forward-return distribution for context.
EPS surprise beat
PendingReported EPS beat consensus estimate by at least 5%; event date is the earnings-surprise timestamp.
11 times historically; 60-day forward avg +16.63%, win rate 54.5%, beating the market by +11.3 pts on average.
Method and limits
- Returns use us_price:adj_close, adjusted for splits and dividends where available.
- Excess returns use world_index:^GSPC as the S&P 500 benchmark proxy.
- Quarterly fundamentals are aligned to SEC filing dates before daily valuation studies.
- The promoted universe starts from active NYSE/NASDAQ common stocks, then applies price and dollar-volume gates.
- Snapshot-only tables such as analyst consensus, DCF, us_ratios, and us_key_metrics are intentionally excluded from historical evidence.
- Overlapping event windows are descriptive distributions, not independent samples.
This page is for historical data analysis and education only. It is not investment advice. Backtests and historical return distributions do not predict future performance; evaluate risk independently before trading.